RxDoctor Payments Data

Basil Holoyda, MD

Neurology · Macon, GANPI 1093753451

Payments from drug & device makers

$1,591in general payments, 2019–2025

Across 66 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$327
  • AbbVie$171
  • Novartis$166
  • Supernus Pharmaceuticals, Inc.$150
  • Genentech USA, Inc.$147
  • EMD Serono, Inc.$125
  • plus $506 from 13 others

What the payments were for

  • Food & beverage$1,591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,591 in reported general payments places this provider in the 45th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$111,749
Medicare patients
266
Services billed
4,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate31$169,679
PanzygaImmun Glob G(Igg)-Ifas/Glycine13$166,526
CopaxoneGlatiramer Acetate15$86,512
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$55,392
Aimovig AutoinjectorErenumab-Aooe37$40,999
Nurtec OdtRimegepant Sulfate28$36,583
GlatopaGlatiramer Acetate12$31,742
XcopriCenobamate16$29,868
RytaryCarbidopa/Levodopa31$29,077
BotoxOnabotulinumtoxina14$18,298
UbrelvyUbrogepant14$18,040
BriviactBrivaracetam12$17,340
Levetiracetam280$12,055
Lacosamide23$10,057
Pramipexole ErPramipexole Di-Hcl17$7,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$27$203,10941 claims
Teva Pharmaceuticals USA, Inc.Copaxone$42$86,51215 claims
AbbVieBotox, Ubrelvy, Namzaric$171$44,05241 claims
SK Life Science, Inc.Xcopri$113$29,86816 claims
UCB, Inc.Briviact$12$17,34012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 506 neurology providers in Georgia.

Other neurology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →